MIRA
INFORM REPORT
|
Report Date : |
21st
June 2006 |
IDENTIFICATION
DETAILS
|
Name : |
REYON
PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
38-6, Dongbinggo-dong, Yongsan-gu, SEOUL, Korea |
|
|
|
|
Country : |
Korea |
|
|
|
|
Financials (as on) : |
31/12/2005 |
|
|
|
|
Date of Incorporation : |
11/25/1964 |
|
|
|
|
Legal Form : |
Co., Ltd by shares |
|
|
|
|
Line of Business : |
Manufacturers of Medicinal Medicaments |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal.
Capable to meet normal commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually
Correct |
|
|
|
|
Litigation : |
Clear |
Ⅰ.
Basic Information
Basic
|
Company Name |
Reyon
Pharmaceutical Co., Ltd. |
|
Address |
38-6, Dongbinggo-dong, Yongsan-gu, SEOUL, Korea |
|
Building |
|
|
Zip Code |
140-811 |
|
Tel |
+82-2-793-5557 |
|
Fax |
+82-2-798-7538 |
|
E-mail |
reyonpharm@reyonpharm.co.kr |
|
Website |
www.reyonpharm.co.kr |
|
Seoul Banch |
6 F
Young Woostar Bldg., 398-5, Shindang
2-Dong Chung-Gu, Seoul, Korea |
|
|
+82-2-793-5557 |
|
|
+82-2-798-7387 |
|
Other Address |
27-27, Hancheon-ri, Deoksan-myeon, Jincheon-gun, CHUNGCHEONGBUK-DO |
|
Tel |
+82-43-536-5177 |
|
Fax |
+82-43-532-3683 |
|
Type |
Export |
|
Industry |
Manufacture of Medicinal Medicaments |
|
Main
Business |
|
|
Sub
Business |
|
|
Established (mm/dd/yyyy) |
11/25/1964 |
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Drugs and Pharmaceutical Products(51000000) |
|
|
|
|
|
|
|
|
|
Others
|
Name |
Yu Sung-Rak |
|
Address |
493, Apgujeong-dong, Gangnam-gu, Seoul, 135-110 Korea |
|
Date of Birth (mm/dd/yyyy) |
10/28/1944 |
|
Title |
President & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
|
Capital |
270,000,000KRW |
|
Employees |
236 |
|
Formation |
Co., Ltd by shares |
Ⅱ. Detailed Information
Management
|
Job
Description |
Title |
Name |
Sex |
Nationality |
Inauguration
Day |
|
President & CEO |
Mr. |
Yu Sung-Rak |
Male |
Korean |
12/14/1993 |
|
Director |
M/S |
Lee
Ae-Sook |
Female |
Korean |
12/14/1993 |
|
Director |
Mr. |
Chung
Soon-Ok |
Female |
Korean |
02/25/1998 |
|
Auditor |
Mr. |
Kim
Byung-Kil |
Male |
Korean |
12/14/1992 |
|
|
|
|
|
|
|
Financials
Unit: KRW
|
Year |
Sales |
Assets |
Net income |
|
2005 |
31,784,852,557 |
33,902,039,941 |
5,327,073,741 |
|
2004 |
24,874,210,878 |
27,279,254,233 |
3,866,616,097 |
|
2003 |
|
|
|
|
2002 |
|
|
|
Financial Description
Unit: KRW
|
Authorized
Capital |
300,000,000 |
||||||||||||||
|
Paid-Up
Capital |
270,000,000 |
||||||||||||||
|
Total Issued Shares |
54,000 |
||||||||||||||
|
|
|||||||||||||||
|
Balance
Sheet Unit:
KRW |
|||||||||||||||
|
|
As of 12/31/2005 |
As of 12/31/2004 |
2003 |
||||||||||||
|
Total Assets |
33,902,039,941 |
27,279,254,233 |
|
||||||||||||
|
Current Assets |
21,869,954,459 |
15,064,953,406 |
|
||||||||||||
|
Quick
assets |
18,351,731,626 |
11,645,436,224 |
|
||||||||||||
|
Inventories |
3,518,222,833 |
3,419,517,182 |
|
||||||||||||
|
Fixed
Assets |
12,032,085,482 |
12,214,300,827 |
|
||||||||||||
|
Investments |
1,231,466,422 |
2,754,611,178 |
|
||||||||||||
|
Tangibles |
8,503,579,905 |
8,190,080,579 |
|
||||||||||||
|
Intangibles |
2,297,039,155 |
1,269,609,070 |
|
||||||||||||
|
Total Liabilities |
16,379,583,886 |
15,083,871,919 |
|
||||||||||||
|
Current Liabilities |
12,234,308,116 |
11,926,952,005 |
|
||||||||||||
|
Fixed Liabilities |
4,145,275,770 |
3,156,919,914 |
|
||||||||||||
|
Capital Stock |
270,000,000 |
270,000,000 |
|
||||||||||||
|
Capital Surplus |
5,707,920 |
5,707,920 |
|
||||||||||||
|
Profit Surplus |
17,246,748,135 |
11,919,674,394 |
|
||||||||||||
|
Capital Adjustment |
- |
- |
|
||||||||||||
|
Total Equity |
17,522,456,055 |
12,195,382,314 |
|
||||||||||||
|
Total Liabilities & Equity |
33,902,039,941 |
27,279,254,233 |
|
||||||||||||
|
|
|||||||||||||||
|
Income Statement Unit: KRW |
|||||||||||||||
|
|
As of 12/31/2005 |
As of 12/31/2004 |
2003 |
||||||||||||
|
Sales |
31,784,852,557 |
24,874,210,878 |
|
||||||||||||
|
Cost of Sold Goods |
16,861,531,507 |
13,738,042,312 |
|
||||||||||||
|
Gross Profit |
14,923,321,050 |
11,136,168,566 |
|
||||||||||||
|
Selling
& Admin. Expenses |
7,549,489,500 |
6,548,045,552 |
|
||||||||||||
|
Operating Income |
7,373,831,550 |
4,588,123,014 |
|
||||||||||||
|
Non-Operating Income |
594,642,077 |
992,843,757 |
|
||||||||||||
|
Non-Operating expenses |
1,419,918,791 |
1,092,434,694 |
|
||||||||||||
|
Ordinary Income |
6,548,554,836 |
4,488,532,077 |
|
||||||||||||
|
Special Income |
- |
- |
|
||||||||||||
|
Income Before Taxes |
6,548,554,836 |
4,488,532,077 |
|
||||||||||||
|
Income Taxes Expenses |
1,221,481,095 |
621,915,980 |
|
||||||||||||
|
Net Income |
5,327,073,741 |
3,866,616,097 |
|
||||||||||||
|
Bank Details |
Industrial bank of Korea Etaewon Branch |
||||||||||||||
|
Corporate Registered
No. |
110111-0048143 |
||||||||||||||
|
Business Registered
No. |
106-81-00516 |
||||||||||||||
|
Permit &
Licenses |
|
||||||||||||||
|
Shareholder
Position |
|
||||||||||||||
|
Company History |
1955 :
Established as Reyon
Hapsung Research Center 1964 : Incorporated as Reyon Hapsung
Research Center Co., Ltd. 1983 : Designated as a promising SME
company by KIST 1989 : Completed Jincheon Factory 1991 : Changed
company name to the present company name 2002 : Designated
as INNO BIZ Enterprise |
||||||||||||||
|
|
|
||||||||||||||
Products, Technologies, Services
Description
|
Main
Products & Services |
|
|
Detailed
Products Spec. |
|
|
Technologies
Acquired |
|
Organization Structure
|
Suppliers |
|
|
Customers |
|
|
Competitors |
|
Related Parties (Subsidiaries,
Joint-Venture & Affiliates)
|
Affiliates |
|
|
Overseas Office |
|
|
Liaison Office |
|
|
Branch |
The subject has 10 branches including Seoul
Branch in domestic area. |
|
Join Venture |
|
|
Subsidiary |
|
|
Corporate Ownership |
|
|
Major Shareholders |
|
|
Cooperative Enterprise |
ViroMed Co., Ltd. (Korea) |
Sales
Spread
|
Unit : Mil KRW |
2005 |
2004 |
2003 |
|
Export |
|
|
|
|
Domestic |
|
|
|
|
Total |
|
|
|
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial
base with the strongest capability for timely payment of interest and
principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution
needed for credit transaction. It has above average (strong) capability for
payment of interest and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are
regarded healthy. General unfavourable factors will not cause fatal effect.
Satisfactory capability for payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal.
Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors
carry similar weight in credit consideration. Capability to overcome
financial difficulties seems comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of
interest and principal sums in default or expected to be in default upon
maturity |
Limited with full security |
|
<10 |
C |
Absolute credit risk exists. Caution
needed to be exercised |
Credit not recommended |